發(fā)布時(shí)間：2018-05-28 05:02

  本文選題：多發(fā)性骨髓瘤骨病 + NB-DNJ　； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:本實(shí)驗(yàn)研究旨在探索討論體外鞘糖脂抑制劑NB-DNJ對(duì)多發(fā)性骨髓瘤U266細(xì)胞RANKL、IL-6表達(dá)的影響,并且比較不同濃度鞘糖脂抑制劑NB-DNJ與硼替佐米在人體外對(duì)MBD的影響。方法:第一部分:培養(yǎng)人骨髓瘤U266細(xì)胞,加入不同濃度鞘糖脂抑制劑NB-DNJ以及硼替佐米陽性干預(yù)藥物。第二部分:用Real-time PCR檢測不同濃度鞘糖脂抑制劑NB-DNJ與干預(yù)藥物硼替佐米作用于U266細(xì)胞RANKL、IL-6的基因表達(dá)水平。第三部分:用Western blot檢測不同濃度鞘糖脂抑制劑NB-DNJ與干預(yù)藥物硼替佐米作用于U266細(xì)胞RANKL、IL-6的蛋白表達(dá)水平。結(jié)果:經(jīng)不同濃度(5umol/L,50umol/L,500umol/L)NB-DNJ作用于U266細(xì)胞,其對(duì)RANKL和IL-6的m RNA及蛋白表達(dá)的抑制作用呈劑量依賴性(P0.05)。研究發(fā)現(xiàn)500umol/LNB-DNJ組與硼替佐米干預(yù)組對(duì)RANKL的mRNA及蛋白表達(dá),差異無統(tǒng)計(jì)學(xué)意義(P0.05),但對(duì)IL-6的mRNA及蛋白表達(dá)抑制作用較硼替佐米強(qiáng)(P0.05)。結(jié)論:鞘糖脂抑制劑NB-DNJ影響MM破骨活化因子的表達(dá);體外證實(shí)鞘糖脂抑制劑NB-DNJ對(duì)MBD的影響效果優(yōu)于硼替佐米。
[Abstract]:Aim: to explore the effect of NB-DNJ on the expression of RANKLLX IL-6 in multiple myeloma U266 cells in vitro, and to compare the effects of different concentrations of sphingolipids inhibitor NB-DNJ and bortezomil on MBD in vitro. Methods: human myeloma U266 cells were cultured with different concentrations of sphingolipids inhibitor (NB-DNJ) and bortezomil positive drugs. Part two: Real-time PCR was used to detect the gene expression level of RANKLX IL-6 in U266 cells treated with different concentrations of sphingolipids inhibitor NB-DNJ and bortezomil. Part three: Western blot was used to detect the protein expression level of RANKL- 6-6 in U266 cells treated with different concentrations of sphingolipids inhibitor NB-DNJ and bortezomil. Results: NB-DNJ was treated with NB-DNJ in U266 cells at different concentrations of 5umolr / L ~ 50umol/ L ~ (50) 渭 mol / L ~ (-1). The inhibitory effect of NB-DNJ on the expression of m RNA and protein of RANKL and IL-6 was in a dose-dependent manner (P0.05). It was found that there was no significant difference in the expression of mRNA and protein in RANKL between 500umol/LNB-DNJ group and bortezomil intervention group, but the inhibitory effect on mRNA and protein expression of IL-6 was stronger than that of bortezomil. Conclusion: sphingolipids inhibitor NB-DNJ can affect the expression of osteoclast activator in MM and the effect of sphingolipids inhibitor NB-DNJ on MBD is superior to that of bortezomil in vitro.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R733.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 許多榮;蘇暢;鄒外一;許輝茹;黃珊;李娟;羅紹凱;;血清sRANKL/OPG比值在判斷多發(fā)性骨髓瘤骨病中的意義[J];中國實(shí)驗(yàn)血液學(xué)雜志;2010年02期

，

本文編號(hào)：1945376